miRNA Polymorphisms and Risk of Cardio-Cerebrovascular Diseases: A Systematic Review and Meta-Analysis

Abstract

Recently extensive focus has been concentrated on the role of miRNAs in the initiation and progression of cardio-cerebrovascular diseases (CCDs) which constitute a range of conditions including cardiovascular diseases (CVDs, especially coronary artery disease (CAD)), congenital heart disease (CHD) and cerebrovascular diseases (CBVDs, especially the ischemic stroke (IS)). An increasing number of studies are evaluating the association between different miRNA polymorphisms and risk of CCDs, but results have been inconclusive. This study represents a comprehensive systematic review and meta-analysis of the association between miRNA polymorphisms and risk of CCDs. PubMed, Embase, Scopus, and Web of Science were queried to identify eligible articles. Odds ratios and 95% confidence intervals were used to assess the association of miRNA polymorphisms with CCD susceptibility. A total of 51 eligible articles evaluating the association of 31 miRNA polymorphisms were identified. Meta-analysis was performed for six miRNA polymorphisms. miR-146a rs2910164 (30 studies: 13,186 cases/14,497 controls), miR-149 rs2292832 (Nine studies: 4116 cases/3511 controls), miR-149 rs71428439 (Three studies: 1556 cases/1567 controls), miR-196a2 rs11614913 (20 studies: 10,144 cases/10,433 controls), miR-218 rs11134527 (Three studies: 2,322 cases/2,754 controls) were not associated with overall CCD. miR-499 rs3746444 was associated with CCD (20 studies: 9564 cases/8876 controls). In the subgroups, rs2910164 and rs3746444 were only associated with CVDs, especially CAD. In conclusion, the results support the existence of a role for miR-146a rs2910164 and miR-499 rs3746444 in determining susceptibility to CCDs, especially CAD.

Up-regulated lncRNA-PVT1 Expression in Peripheral Blood Mononuclear Cells of Patients with Coronary Artery Disease is Correlated with Decreased Interleukin-10 Production

“…Several studies have reported the association between miR-14a and CAD; the results of a recent systematic review and meta-analysis supported the existence of a role for miR-146a rs2910164 polymorphism in determining the susceptibility to cardio-cerebrovascular diseases, especially CAD (26).…”

Evidences from a Systematic Review and Meta-Analysis Unveil the Role of MiRNA Polymorphisms in the Predisposition to Female Neoplasms

“…Rs2910164 substitutes a C nucleotide in the 3′ arm of hsa-miR-146a precursor (MI0000477) with a G nucleotide [97]. This substitution induces a mispairing in the precursor structure and it affects the third base of the seed region of hsa-miR-146a-3p (MIMAT0004608).…”

“…Accumulating evidence suggests that rs2910164 might influence the maturation and expression of miR-146a in a context dependent paradigm, in which the true effect of either allele might depend on the cell type and the disease status [97]. Observations that support this paradigm include the discrepancies between pathological and normal samples in terms of miR-146a genotype-expression correlation [98,99] and opposite effects of rs2910164 alleles on miR-146a expression in different cell types or diseases [97,98,99,100,101]. Moreover, miRNA-mediated regulation of gene expression has been shown to be highly influenced by cell-type specific conditions [102].…”

Fecal microRNAs as Innovative Biomarkers of Intestinal Diseases and Effective Players in Host-Microbiome Interactions

“…It is now clear that dysregulated expression of miRNAs can exert profound effects on cells function and, as a result, leads to various pathological and occasionally malignant outcomes [54][55][56][57]. The involvement of miRNAs was showed in more than 70 different diseases such as cancer, viral infection, gastrointestinal malignancies, diabetes, immune-related diseases, and neurodegenerative disorders [51,53,[58][59][60][61][62][63][64]. In view of this, miRNAs are considered an interesting target for therapeutic intervention; to date, approximately 20 miRNA-and siRNA-based therapeutics are currently in the preclinical and/or in clinical trials [45,47].…”